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In Brief
Intestinal microbiota dysbiosis is
characteristic of Crohn’s disease, but the
contributing factors remain unclear. By
examining pediatric Crohn’s disease
patients, Lewis et al. show that dysbiosis
is independently associated with
antibiotics, inflammation, and diet and
decreases with reduced intestinal
inflammation. These results may facilitate
biomarker discovery and therapeutic
interventions.
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Abnormal composition of intestinal bacteria—‘‘dys-
biosis’’—is characteristic of Crohn’s disease. Disease
treatments include dietary changes and immunosup-
pressive anti-TNFa antibodies as well as ancillary
antibiotic therapy, but their effects on microbiota
composition are undetermined. Using shotgun meta-
genomicsequencing,weanalyzed fecal samples from
a prospective cohort of pediatric Crohn’s disease pa-
tients starting therapy with enteral nutrition or anti-
TNFa antibodies and reveal the full complement and
dynamics of bacteria, fungi, archaea, and viruses dur-
ing treatment. Bacterial community membership was
associated independently with intestinal inflamma-
tion, antibiotic use, and therapy. Antibiotic exposure
was associated with increased dysbiosis, whereas
dysbiosis decreased with reduced intestinal inflam-
mation. Fungal proportions increased with disease
and antibiotic use. Dietary therapy had independent
and rapid effects on microbiota composition distinct
from other stressor-induced changes and effectively
reduced inflammation. These findings reveal that dys-
biosis results from independent effects of inflamma-
tion, diet, and antibiotics and shed light on Crohn
disease treatments.
INTRODUCTION
The human gut microbiota is densely populated by microbes
from all three domains of life together with their viruses (Hoff-Cell Hostmann et al., 2013; Human Microbiome Project Consortium,
2012; Samuel et al., 2007). Crohn’s disease results from a path-
ologic interaction between the mucosal immune system and the
environment, particularly the microbes residing in the gut lumen
(Sartor, 2006, 2008), and is characterized by altered—or ‘‘dysbi-
otic’’—gut bacterial composition (Huttenhower et al., 2014; Khor
et al., 2011; Sartor, 2006, 2008). Numerous human genetic loci
encoding proteins involved in host immune responses have
been linked to Crohn’s disease (Jostins et al., 2012), but the
impact of these genes on the dysbiosis associated with Crohn’s
disease is limited (Knights et al., 2014). Rather, dysbiosis is hy-
pothesized to be a response of the microbes, particularly bacte-
ria, to environmental stressors such as the host inflammatory
response (Huttenhower et al., 2014) and/or the production of
electron acceptors that facilitate anaerobic respiration (Winter
and Ba¨umler, 2014). Dysbiosis is commonly characterized by
an expansion of Proteobacteria and a decrease in Firmicutes,
along with a decrease in community richness (Nagalingam and
Lynch, 2012). Much less is known about the responses of other
domains of microbial life to environmental stressors. Similarly, it
is unknown whether dysbiosis resulting from inflammation is
rapidly reversible. Patients with Crohn’s disease are exposed
to antibiotics and dietary changes that are likely to affect the mi-
crobiota, but the influence of these factors and their interactions
with each other are incompletely understood.
Antibiotics are often used as an ancillary therapy for Crohn’s
disease (Khan et al., 2011). However, the main therapies for
Crohn’s disease includes episodic or chronic immunosuppres-
sion with corticosteroids, antimetabolite agents, or antibodies
directed against host immune proteins such as tumor necrosis
factor a (anti-TNF) (Borrelli et al., 2006; Grover et al., 2014; Rut-
geerts et al., 2012). The anti-TNF medications are administered
parenterally and are not expected to alter the gut microbiota
composition directly. An alternative therapy, used predominantly& Microbe 18, 489–500, October 14, 2015 ª2015 Elsevier Inc. 489
Table 1. Characteristics of Healthy Controls and Patients with Crohn’s Disease^ in the Two Clusters Based on Bacterial Taxonomy*
Healthy Controls
(n = 26)
Near Cluster
(n = 57)
Far Cluster
(n = 28) p value
Adjusted Odds
Ratio (95% CI)y
Age (years) 14.3 (7.9-19.9) 12.6 (10.7-15.1) 13.9 (10.1-15.5) 0.58
Female sex 12 (46%) 21 (37%) 13 (46%) 0.48
White race 17 (65%) 52 (91%) 23 (82%) 0.29
Canadian 0 (0%) 23 (40%) 9 (32%) 0.49
Prior bowel surgery 0 (0%)x 3 (5%) 3 (11%) 0.38
Duration of Crohn’s disease
(years)
N/A 0.1 (0.0-1.1) 0.2 (0.1-1.0) 0.87
Disease location
Ileum N/A 52 (91%) 23 (82%) 0.29
Cecum N/A 39 (68%) 24 (86%) 0.12
Colorectal N/A 54 (95%) 27 (96%) >0.99
Upper gastrointestinal N/A 33 (58%) 16 (57%) >0.99
Phenotype
Penetrating N/A 2 (4%) 2 (7%) 0.60
Stricturing N/A 5 (9%) 1 (4%) 0.66
Perianal disease N/A 14 (25%) 8 (29%) 0.79
Symptoms
PCDAI N/A 32.5 (20-45) 30 (21.25-40) 0.73
Bleeding N/A 16 (28%) 8 (29%) >0.99
Consistency 0.14
Formed N/A# 20 (35%) 4 (14%)
Partially formed N/A# 21 (37%) 14 (50%)
Unformed 0 (0%) 16 (28%) 10 (38%)
Stools per day 0.59
0–2 25 (96%) 26 (46%) 11 (39%)
3–5 1 (4%) 27 (47%) 13 (46%)
6–8 0 (0%) 2 (4%) 3 (11%)
>8 0 (0%) 2 (4%) 1 (4%)
Medications
Mesalamine N/A 28 (49%) 14 (50%) >0.99
Oral corticosteroids N/A 14 (25%) 18 (64%) 0.001 8.2 (1.7-39.6)
Rectal corticosteroids N/A 0 (0%) 1 (4%) 0.33
Thiopurine N/A 7 (12%) 1 (4%) 0.26
Antibiotics within prior 6 months 0 (0%) 21 (37%) 23 (82%) <0.001 8.4 (1.9-38.1)
Current antibiotic use 0 (0%) 9 (16%) 15 (54%) 0.001
Abundance of fungi
(quartiles)
<0.001 7.1 (2.8-18.5)z
1st 9 (35%) 18 (32%) 1 (4%) Ref
2nd 10 (38%) 16 (29%) 1 (4%) 0.8 (0.04-18.0)
3rd 7 (2%) 16 (29%) 5 (18%) 9.2 (0.7-124.2)
4th 0 (0%) 6 (11%) 21 (75%) 111.5 (7.1-1759.1)
Abundance of human DNA
(quartiles)
<0.001
1st 14 (54%) 14 (25%) 0 (0%)
2nd 8 (31%) 16 (29%) 3 (11%)
3rd 4 (15%) 18 (32%) 6 (21%)
(Continued on next page)
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Table 1. Continued
Healthy Controls
(n = 26)
Near Cluster
(n = 57)
Far Cluster
(n = 28) p value
Adjusted Odds
Ratio (95% CI)y
4th 0 (0%) 8 (14%) 19 (68%)
FCP (mg/g) N/A 822.5 (348-1458 748.5 (342.5-1881) 0.89
N/A: not applicable.
^One subject was missing a baseline stool sample; therefore, 85 patients were included in the analysis.
*Continuous variables reported as medians and interquartile range. Unadjusted p values from Fisher exact test or Wilcoxon rank-sum test comparing
children with Crohn’s disease in the near and far clusters, respectively.
yAdjusted odds ratios derived from logistic regression using backwards elimination startingwith all variableswith unadjusted p value < 0.2 and retaining
all variables with a p value < 0.1.
#Diarrhea was an exclusion criteria for healthy control children.
xOne child had prior appendectomy.
zQuartiles as a continuous variable.in children, is the defined formula diet, also known as enteral
nutrition therapy. Both elemental and polymeric formulae, con-
taining, respectively, amino acids and intact protein, have
proved efficacious in treating symptoms and intestinal inflam-
mation in Crohn’s disease in addition to supporting nutritional
needs for growth and weight maintenance (Borrelli et al., 2006;
Grover et al., 2014). The efficacy of these diets is greatest
when used as the exclusive source of nutrition(Grover et al.,
2014; Lee et al., 2015). Dietary therapy has the advantage of
avoiding immunosuppression but is difficult to maintain long
term. If the mechanism of action of dietary-based therapies
were understood, it might be possible to develop less restrictive
diets that deliver the same therapeutic benefit. One hypothesis
is that diet therapy alters the composition of the gut microbiota
in a manner that contributes to the therapeutic benefit, though
data supporting this are limited (Gerasimidis et al., 2014; Kaa-
koush et al., 2015).
We reasoned that longitudinal characterization of the gut mi-
crobiome of pediatric Crohn’s disease patients initiating therapy
would allow us to characterize the concurrent effects of intestinal
inflammation, antibiotics, and diet on gut microbial community
structure. We conducted a longitudinal study of 90 children
with Crohn’s disease who were initiating treatment with either
a defined formula diet or anti-TNF therapy and compared them
to 26 healthy control children. We tracked symptoms, mucosal
inflammation, and changes in the gut microbiome over an 8-
week study period. The gut microbiome was quantified using
shotgun metagenomic DNA sequence analysis of longitudinal
samples. Dysbiosis was quantified as the distance of each sam-
ple from the centroid of samples from healthy controls. Commu-
nities partitioned into two distinct clusters based on the bacterial
composition, as seen previously (Frank et al., 2007; Gevers et al.,
2014), one of which overlapped the healthy controls. The dysbi-
otic community was associated with increases in specific fungi,
prior antibiotic therapy, and higher concentration of human DNA
in feces. By tracking the microbiota composition over the course
of therapy, we found that dysbiosis was reduced in response to
decreased bowel inflammation, and that inflammation, antibiotic
exposure, and diet independently influenced different taxa.
Fungi were elevated with disease and antibiotic use, but dimin-
ished with diet therapy. Thus while dysbiosis in the gut is com-
mon in Crohn’s disease, the response of the gut microbiome
depends on the environmental stressor.Cell HostRESULTS
Clinical Outcomes in Patients Treated with a Defined
Formula Diet versus Anti-TNF
Ninety children initiated one of the study therapies (52 anti-TNF;
22 exclusive enteral nutrition [EEN]; 16 partial enteral nutrition
with ad lib diet [PEN]) (Supplemental Experimental Procedures
and (Lee et al., 2015). EEN- and PEN-treated children consumed
approximately 90% and 53% of daily calories from dietary for-
mulas, respectively. Inflammation was quantified by measuring
fecal calprotectin (FCP). Response to therapy was defined as a
reduction of FCP to below 250 mg/g because this measure is
associated with diminished mucosal inflammation (Lin et al.,
2014). Reduction in FCP below 250 mg/g was more common
among those receiving anti-TNF (62%) and EEN (45%) than
PEN (10%) (Lee et al., 2015).
Microbial Community Patterns in Crohn’s Disease
and Healthy Controls
Adequate stool samples were available from 86 individuals to
conduct shotgun metagenomic analysis. Samples were
collected at four time points: baseline, 1 week, 4 weeks, and
8 weeks into therapy (Table S1A). We also compared stool sam-
ples from 26 healthy children (Table 1) collected in a prior study
(Wu et al., 2011) but analyzed by shotgun metagenomic
sequencing here. None of the healthy children had received an-
tibiotics in the prior 6 months. DNA was prepared from whole
stool, and sequenced using the Illumina HiSeq paired-end
method. After filtering out low-quality, human, and contami-
nating reads, we were left with 6.5 3 1011 bases of microbial
DNA sequence for analysis.
We quantified the bacterial taxonomic composition using
MetaPhlAn (Segata et al., 2012). Figure 1 shows a comparison
of bacterial lineages in the healthy control subjects and pediatric
Crohn’s disease cohort prior to initiation of therapy (‘‘baseline’’ in
the below). Figure 1A shows taxonomic proportions for each
sample at baseline with metadata summarized above the heat
map (all time points are shown in Figure S1A).
After filtering out very-low-abundance genera, comparison of
median relative abundances showed 14 of 45 genera differed
between children with Crohn’s disease and healthy controls
(FDR controlled p (q) < 0.05 by Wilcoxon rank-sum test; Table
S1B). The Crohn’s patients had reduced relative abundance of& Microbe 18, 489–500, October 14, 2015 ª2015 Elsevier Inc. 491
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Figure 1. Bacterial Composition in Samples
from Children with Crohn’s Disease and
Healthy Controls
(A) A heatmap demonstrating relative abundance
of bacterial taxa prior to therapy according to
presence or absence of Crohn’s disease, cluster
assignment, use of corticosteroids and antibiotics,
FCP concentration, and response to therapy.
Metadata are indicated by the color code at the top
of the figure. White cells indicate missing data.
Taxa that were statistically different in abundance
between Crohn’s disease and healthy controls are
identified by *; taxa that were statistically different
in abundance between the two Crohn’s disease
clusters are identified by y (q < 0.05). FCP in this
and subsequent figures indicates FCP. Samples
were ordered by the metadata (healthy versus
Crohn’s samples, and cluster 1 versus cluster 2,
then other forms of metadata).
(B) MDS analysis of samples from children with
Crohn’s disease and healthy controls. Bacterial
taxa present were quantified by MetaPhlAn, dis-
tances were calculated using binary Jaccard In-
dex, and samples were plotted based on MDS.
Samples from healthy controls are shown by the
filled circles, and Crohn’s disease as open circles.
Clusters were defined by partitioning around me-
doids with estimation of number of clusters
(PAMK), and are colored blue (healthy associated)
and red (dysbiotic). The size of the dot is scaled by
the proportion of human DNA in the sample.
(C) Percentage of human DNA reads in each met-
agenomic sequence sample. Near cluster (blue,
associated with healthy controls) and far cluster
(red, dysbiotic) refer to the groups shown in (B).Prevotella, Eubacterium, Odoribacter, Akkermansia, Roseburia,
Parabacteroides, Alistipes, Coprococcus, Dorea, and Rumino-
coccus and increased abundance of Escherichia, Klebsiella,
Enterococcus and Veillonella. Random forest was used to iden-
tify bacterial lineages that best distinguished healthy children
from Crohn’s patients with active disease, and predicted
Crohn’s disease and normal with 86% prediction accuracy.
Mostly similar lineages (Prevotella, Odoribacter, Eubacterium,
Escherichia, and Faecalibacterium) were found to distinguish
the groups.
Community patterns were analyzed using partitioning around
medoids with estimation of number of clusters (PAMK) to find
the optimal number of clusters, and visualized after multidimen-
sional scaling (MDS) (Figure 1B). Samples from patients with
active Crohn’s disease partitioned into two clusters (Figure S1B):
one that was near to the healthy controls (near cluster) and one
that clustered separately (far dysbiotic cluster), paralleling previ-
ous studies (Frank et al., 2007; Gevers et al., 2014). Thirty of 45
genera differed in abundance (q < 0.05) between the two clusters
(Table S1C). The far dysbiotic cluster was characterized by an
increased relative abundance of Streptococcus, Klebsiella,
Lactobacillus and reduced relative abundance of Faecalibacte-
rium, Parabacteroides, Dorea, Blautia, Holdemania, Collinsella,
Coprococcus, Odoribater, Prevotella, Bacteroides, Dialister,
Eubacterium, Alistipes, and Ruminococcus. Random forest
with bacterial abundance had 92% prediction accuracy for pre-
dicting these two clusters. The top five most predictive genera492 Cell Host & Microbe 18, 489–500, October 14, 2015 ª2015 Elsevwere Blautia, Faecalibacterium, Dialister, Lactobacillus, and
Bacteroides.
Reduced diversity was observed in both clusters relative to
healthy subjects, and in the dysbiotic far cluster compared to
the near cluster (see Supplemental Information). An analysis us-
ing phylogenetic attributions at the species level yielded similar
conclusions (Figures S1C and S1D).
In summary, baseline samples clustered into two groups, with
the far dysbiotic cluster being more distant from the healthy con-
trols and characterized by altered bacterial composition and
lower diversity.
High Levels of Human DNA in Stool Correlated
with Dysbiosis
In processing the metagenomic DNA from stool, we observed
that the proportion of human DNA varied widely (Figure 1C).
The percentage of human reads was low in the healthy controls
(mean = 0.87%, max = 10.1%, minimum = 0.05%) relative to
patients with active Crohn’s disease (mean = 16.6%,
maximum = 94.2%, minimum = 0.01%; p < 5 3 1011), with
over 50% of the sequence reads mapped to human in 49
Crohn’s disease samples. Selected DNA samples were tested
for human DNA content using QPCR to detect human beta-
tubulin-coding sequences, revealing that the amounts detected
were positively correlated with the calls from metagenomic
sequencing (r = 0.81 Pearson’s correlation, p = 9.3 3 1011).
We hypothesized that the source of human DNA was eitherier Inc.
epithelial cells or blood shed into feces associated with disease
activity.
Analysis of Fecal Microbial Gene Pathways
The gene content of the gut microbiota was compared to assess
associations between gene function and dysbiosis (Figure 2A)
using HUMAnN (Abubucker et al., 2012) Differences were found
between IBD and healthy controls in 42 of 163 pathways exam-
ined (Table S1D). Crohn’s samples clustered into two groups
based on gene pathway data, one of which more closely resem-
bled the healthy controls and one more dysbiotic (Figure 2B;
Table S1E). The clusters separated based on pathway data
tracked closely with the near and far clusters defined by bacterial
taxonomic representation (Figure 2B, red and blue colors).
To guide interpretation, we analyzed the Spearman correlation
between bacterial abundance and gene pathway enrichment in
these data (Figure S2A). Pathway data partitioned the bacteria
into two notable groups, one including gammaproteobacteria
together with Streptococcus and Enterococcus and a second
group dominated byBacteroides andmultiple anaerobic Bacter-
oidetes and Firmicutes typical of healthy gut. Below we propose
relationships between specific gene pathways and persistence
in the presence of different environmental stressors. However,
enrichment may also be due to passenger effects, where
outgrowth of specific organisms resulted in enrichment in path-
ways that were not themselves major contributors to differential
fitness.
Random forest was used to identify those pathways that best
discriminated between healthy children and the active Crohn’s
disease cohort at baseline (Figures 2C and S2B). Samples mem-
bership in the two categories could be predicted with 87% accu-
racy using gene pathway data, comparable to the partitioning
achieved using bacterial taxonomic data. The top six most
notable pathways, higher in the Crohn’s samples, were sulfur
relay systems, galactose metabolism, biosynthesis of sidero-
phores, glycerolipid metabolism, glutamine/glutamate meta-
bolism, and nitrogen metabolism (Table S1D). Similarly, 94 of
163 gene pathways were differentially abundant between the
two clusters, 51with greater representation in themore dysbiotic
far cluster (Table S1E). Random forest using gene pathway
abundance had 87% prediction accuracy for classification of
the two bacterial clusters (near and far dysbiotic) defined by
taxonomic proportions. The five most predictive pathways
were glycerophospholipid metabolism, aminobenzoate degra-
dation, sulfur relay system, and glutathione metabolism, which
were increased in the far dysbiotic cluster, and selenocompound
metabolism, which was decreased in the far cluster. Thirty-three
of 42 pathways that were significantly different between Crohn’s
disease and healthy controls were also significantly different be-
tween the two clusters of Crohn’s disease, suggesting that they
are related primarily to the composition of the dysbiotic micro-
biota rather than being intrinsic alterations associated with IBD
per se.
Fungal Community Structure
We characterized the fungal reads in the metagenomic data by
alignment to sequenced fungal genomes, followed by extensive
filtering to remove artifacts (described in Supplemental Informa-
tion; Tables S1F and S1G). Five fungal taxa were detected in theCell Hostsamples—Saccharomyces cerevisiae,Clavispora lusitaniae (also
known as Candida lusitaniae), Cyberlindnera jadinii (also known
as Pichia jadinii and Candida utiliz), Candida albicans, and Kluy-
veromyces marxianus. Figure 3A shows the representation of
fungal taxa in healthy controls and Crohn’s disease samples at
baseline, and the relationship to metadata. All of the fungal
taxa were more represented in the samples from Crohn’s dis-
ease subjects, particularly those in the more dysbiotic far cluster
as defined by the bacterial taxonomic analysis in Figure 1 (Fig-
ures 3B–3F). Abundance of the different fungi were highly corre-
lated with each other (Spearman correlation 0.66–0.84, Table
S1H). Higher fungal proportions in samples also correlated
with higher levels of human DNA (Figure 3G). Random Forest
analysis based on fungal data had 92% prediction accuracy
for classification of normal and baseline Crohn’s disease sam-
ples. The most predictive fungus was Clavispora lusitaniae.
Thus, the five yeasts detected are positively associated with
Crohn’s disease, particularly in the setting of greater bacterial
dysbiosis.
Some correlations were observed between bacteria and fungi
in the cohort, but these varied between the healthy controls and
the two clusters of patients with Crohn’s disease (Supplemental
Information; Figures S3A–S3C).
Analysis of Archaea
Archaea comprise a third domain of life, and are primarily repre-
sented in the gut byMethanobrevibacter smithii (Hoffmann et al.,
2013; Human Microbiome Project Consortium, 2012; Samuel
et al., 2007). We aligned the full set of non-human sequence
reads to theM. smithii genome and found that most of the pedi-
atric subjects studied had little or no detectable colonization. No
difference was observed in mean values for the Crohn’s disease
(baseline time point) and healthy cohorts (p = 0.81 for compari-
son of mean proportions), paralleling a previous study (Chehoud
et al., 2015).
Analysis of Viral Representation
We investigated the representation of DNA viruses in the patient
samples after alignment of sequence reads to databases of viral
genomes. No virus was identified that was significantly enriched
in Crohn’s disease samples versus healthy controls. A recent
report proposed that tailed phages (Caudovirales) were enriched
in viral concentrates from stool of IBD patients (Norman et al.,
2015). We thus investigated the representation of bacteriophage
sequences in our data. The analysis was limited by use of whole-
stool instead of purified viral particles and by the high natural
phage diversity that results in difficulty in identification in meta-
genomic data. No significant difference was found in the abun-
dance of Caudovirales between healthy controls and Crohn’s
disease samples at the baseline time point (p = 0.98; Wilcoxon
rank-sum test) or for comparison of the near and far cluster as
defined by the bacterial taxonomic composition (p = 0.35; Wil-
coxon rank-sum test).
Two subjects on anti-TNF therapy showed substantial repre-
sentation of animal cell viruses in stool samples (anellovirus
and bocavirus). To investigate this further, viral particles were
purified from the two samples and sequenced, which validated
detection of each. These findings raise the question of whether
the anti-TNF therapy itself may have promoted these viral& Microbe 18, 489–500, October 14, 2015 ª2015 Elsevier Inc. 493
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Figure 2. Comparison of Gene Pathways Present in Samples from Crohn’s Disease Subjects and Healthy Controls at Baseline Assessed by
Shotgun Metagenomics
(A) Heatmap of pathways that differed significantly (q value < 0.05) between healthy controls and Crohn’s disease subjects at baseline. Each row was normalized
by z score.
(B) Cluster analysis based on MDS using the pathway data. Colors indicate samples that are members of the near cluster (overlapping healthy controls) or far
cluster (dysbiotic) as defined by the analysis of bacterial taxa. Controls are defined by filled circles and Crohn’s disease samples by open circles.
(C) Analysis using the machine learning algorithm Random Forest. Gene pathways that most strongly distinguish patients with Crohn’s disease from healthy
controls were identified. Importance scores were derived from the loss in accuracy measured when each indicated pathway was removed from the analysis. The
units on the x axis indicate mean decrease in accuracy.
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Figure 3. Fungal Representation in Samples from Crohn’s Disease Subjects and Healthy Controls at Baseline
(A) Heatmap summarizing the abundance of fungal taxa present in healthy controls (left side of figure) and children with Crohn’s disease (right side of figure).
Metadata are indicated by the color code at the top of the figure. White cells indicate missing data.
(B–F) Bar graphs (B)–(F) show the relative abundance of the five main taxa detected. The y axis shows reads per kb of target DNA per million reads in the sample
(RPKM).
(G) Graph showing correlation between human DNA % and fungal DNA %. Points are colored by membership in the near or far clusters based on the bacterial
taxonomic data. Samples from healthy subjects are shown filled and Crohn’s disease by open circles.blooms, similar to blooms in solid organ transplant recipients
receiving immunosuppression (De Vlaminck et al., 2013; Young
et al., 2015).
Exploring the Baseline Clusters Defined by Bacterial
Abundance in a Multivariate Model
We next explored factors associated with membership in the
dysbiotic far cluster at baseline (Figure 1B). In the multivariable
model, use of antibiotics within the preceding 6 months, current
use of corticosteroids, and abundance of fungi were indepen-
dently associated with membership in the far cluster (Table 1).
These data indicate that at least part of the previously described
dysbiosis in IBD may be due to antibiotic and corticosteroid
exposure and that the dysbiosis extends beyond the bacteria
to include fungi.
Given the association with antibiotics, we further defined the
bacterial taxa that distinguished Crohn’s disease from healthy
controls by analyzing only the subset of patients not treated
with antibiotics (Table S1I). Separately, we analyzed the asso-
ciation of antibiotic use and taxonomic representation within
the Crohn’s disease cohort (Table S1J). Bacterial genera asso-
ciated with Crohn’s disease in the absence of antibiotic use
were almost completely different from genera associated with
antibiotic use in the Crohn’s disease cohort (discussed further
below).
Clustering Did Not Predict Response to Therapy
Rates of response to treatment were not significantly different
among patients in the near or far dysbiotic cluster. Twenty-seven
patients (53%) in the near cluster and nine (45%) patients in the
far dysbiotic cluster achieved a reduction in FCP below 250 mg/g
(p = 0.60). Among anti-TNF-treated patients the response rates
were 66.7% and 60%, respectively (p = 0.74). Too few EEN-
treated patients were available for meaningful comparison.Cell HostDynamics of Dysbiosis with Treatment
We categorized sequences from each fecal sample by its Jac-
card distance from the centroid of the healthy control samples,
providing a quantitativemeasure of dysbiosis, and then analyzed
longitudinal dynamics. One of the proposed mechanisms of ac-
tion of diet-based therapy is to alter the gut microbiota compo-
sition. We thus assessed the bacterial composition at baseline
and 1 week into therapy (Figure 4A). The microbiota composition
among the EEN-treated group changedwithin 1week of therapy,
moving significantly farther from centroid of the healthy controls
(relative to baseline p = 0.005 overall, p = 0.02 among re-
sponders, p = 0.14 among non-responders). Oneweek after initi-
ation of EEN, abundance of 6 of the 40 genera examined were
nominally different at a threshold of p = 0.05 (Haemophilus,
Alistipes, Streptococcus, Dialister, Dorea, and Gordonibacter;
not significant after correction for multiple comparisons; Table
S1K). A similar pattern was not seen among the PEN-treated pa-
tients (p = 0.83) or anti-TNF-treated patients (p = 0.02, note anti-
TNF-treated group moved closer to healthy centroid within
1 week), suggesting that either there is a dose-dependent effect
of enteral nutrition or that fully removing regular table food from
the diet influences microbiota composition within 1 week.
We next used linear regression to examine the independent ef-
fects of reduction in FCP, antibiotic exposure, and the degree of
dysbiosis at baseline on the final state of the microbial commu-
nity (Figure 4B). Given the different microbial response to the
three therapies during the first week, analyses were conducted
combined and stratified by treatment. At the end of the study, re-
sponders (i.e., those with reduction in FCP) were closer to the
centroid of the healthy controls than nonresponders after adjust-
ing for antibiotic use and initial degree of distance from the
centroid (p = 0.003). Similar patterns were seen for anti-TNF ther-
apy (p = 0.06) and EEN (p = 0.06). There were too few responders
to PEN for meaningful analysis. Analysis at the species level& Microbe 18, 489–500, October 14, 2015 ª2015 Elsevier Inc. 495
AB
Figure 4. Change in the Microbiota Compo-
sition among Children with Crohn’s Disease
Treated with EEN, PEN, and Anti-TNF
Therapy
(A) Characterization of the bacterial taxonomic
composition based on distance from the centroid of
healthy controls. Boxes show median and first and
third quartile. The x axis shows the group and time
point, the y axis shows the distance from the
centroid of the healthy controls. The groups
compared are shown to the right.
(B) Plot of regression coefficients and their confi-
dence intervals. The dependent variable used is
distance to the healthy centroid. Covariates
included antibiotic use, response to therapy
defined as reduction in FCP to less than 250 mg/g,
and the starting distance from the healthy centroid.
Regression coefficients are shown as dots, one SD
is shown as the thin lines, and two SDs as the thick
lines.yielded generally similar results, but with amore pronounced dif-
ference in the composition of responders and non-responders to
EEN after 1 week of therapy (p = 0.025), a difference that per-
sisted at week 8 (Figures S4 and S4B).
The resolution of dysbiosis was not complete among re-
sponders. Among the anti-TNF-treated patients who were re-
sponders, 11 taxa differed in abundance from healthy controls
at baseline (q < 0.05). At the end of follow-up, nine of these
taxa (82%) remained significantly different at a nominal p <
0.05, and six (55%) were significant at a q < 0.05 (Klebsiella, Pre-
votella, Escherichia, Odoribacter, Enterococcus, and Fusobac-
terium). Thus, clinical response was associated with evolution
of communities toward healthy structure (Figure 4B), consistent
with the observation that humanDNA levels diminishedwith suc-
cessful therapy (q = 0.0002; quantile regression), but normal
community structure was not usually fully restored (Figure 4A).
This may be due to continuing environmental stress from the
host inflammatory response as indicated by mildly elevated
FCP despite response to treatment. An analysis at the species
level yielded generally similar conclusions (Figures S4A and
S4B). Fungal colonization was not reduced with successful ther-
apy (p = 0.35; quantile regression).
To explore the independent effect of inflammation on the
composition of the gut microbiota, we created separate
robust quantile (75%) regression models adjusted for antibi-
otic use and treatment modality with fold-change in abun-
dance of individual taxa as the dependent variable. Response
to therapy defined as final FCP < 250 mg/g was associated
with decrease in Actinomyces (p = 0.0002, q = 0.01) and in-496 Cell Host & Microbe 18, 489–500, October 14, 2015 ª2015 Elsevier Inc.crease in Lactococcus (p = 0.002, q =
0.046) and Roseburia (p = 0.006, q =
0.084). (Table S1L). Multiple gene path-
ways were also associated with antibi-
otic use, treatment, and response
(Table S1M).
Distinctive responses of genus-level
taxa are summarized in Figure 5, which
also indicates the time points queried.Specific bacterial lineages showed increases or decreases in
abundance associated with (1) health or Crohn’s disease at
baseline, (2) antibiotic use in the Crohn’s disease cohort at base-
line, (3) diet therapy in the Crohn’s cohort at week 1, and (4) res-
olution of inflammation (corrected for antibiotic use) in the
Crohn’s cohort at week 8.
Distinctive responses were also seen associated with fungal
colonization (Figure 5; Tables S1N–S1Q). At baseline, Candida,
Clavispora, Cyberlindnera, and Kluyveromyces were all enriched
in Crohn’s samples versus healthy controls (Table S1N). Com-
parisons between antibiotic-treated versus not treated patients
showed enrichment of all these fungi plus Saccharomyces as
well (Table S1O). In contrast, after one week of diet therapy,
Candida, Clavispora, and Cyberlindnera were all reduced in
abundance (Table S1P). Similarly, abundance of Clavispora
Cyberlindnera, and Kluyveromyces were significantly reduced
from baseline to week 8 only in the EEN-treated group (q <
0.05) and not the anti-TNF-treated group. At week 8, overall
response to therapy after adjusting for treatment and antibiotic
use was not associated with a change in fungal abundance
(Table S1Q).
DISCUSSION
Here we assess the concurrent effects of inflammation, diet, and
antibiotic use on the the gut microbiome in pediatric Crohn’s dis-
ease. The environmental stresses experienced by Crohn’s dis-
ease patients were associated with changes in microbial taxon-
omy that mostly differed among the stressors studied (Figure 5).
Figure 5. Bacterial and Fungal Genera Asso-
ciated with Environmental Stressors
Microbial genera are shown that differed in four
comparisons: Crohn’s disease versus healthy
controls at baseline (‘‘Disease’’); antibiotic use at
baseline in the Crohn’s disease cohort (‘‘Antibi-
otics’’); diet (EEN) or anti-TNF therapy at week 1
(Diet’’); and reduction of inflammation or not at the
end of the study at week 8 (‘‘Inflammation’’). The
time line is shown along the bottom (yellow). Bac-
terial lineages are shown in light blue and fungal
lineages in pink. Data for the diagrams are in Tables
S1I–S1L and S1N–S1Q. Taxa shown were signifi-
cantly associated after adjustment for multiple
comparisons for Crohn’s disease versus healthy
controls, for antibiotic use comparisons, and for all
fungal comparisons. The bacterial taxa shown for
the effect of EEN, and resolution of inflammation
were significant at a nominal p value < 0.05 (i.e.,
without correction for multiple comparisons).We observed that patients with Crohn’s disease can be catego-
rized into two groups defined by the composition of the bacterial
populations, paralleling previous studies based on 16S rRNA
gene tag sequencing (Frank et al., 2007; Gevers et al., 2014;
Tong et al., 2013). We further showed that dysbiosis involved dif-
ferences in microbial gene representation, increases in fungal
representation, and higher levels of human DNA in stool. Antibi-
otic exposure, which is common in this population, has also been
identified as a risk factor for new onset Crohn’s disease (Card
et al., 2004; Margolis et al., 2010) and was strongly associated
with the dysbiosis observed here. EEN further altered the
composition of the gut microbiota, possibly due to elimination
of regular table food, despite having a favorable effect on gut
inflammation. By our definition, the effect of diet qualifies as dys-
biosis, though we note that the changes were distinct from the
other stressors studied (Figure 5). Finally, effective therapy with
either anti-TNF or EEN reduced, but did not completely
eliminate, the dysbiosis present at baseline. Thus, our data
demonstrate that diet, antibiotics, and inflammation each inde-
pendently influence different components of the microbial
community.
We described two clusters of patients based on microbiota
composition, though the data can be characterized as either a
continuum or a dichotomous grouping. The two clusters were
associated with clinical features such as antibiotic use and hu-
man DNA but did not appear to predict response to therapy.
Thus, the biologic and clinical significance of the clusters re-
mains to be determined.
There were very few taxa whose abundance was associated
with more than one stressor. However, the genus Alistipes was
increased with EEN but diminished by antibiotic treatment,
raising the possibility that antibiotics antagonize the beneficial
effects of EEN.
The independent effects of antibiotics, diet, and inflammation
likely reflect different mechanisms. Antibiotics are direct toxins
to bacteria and may facilitate outgrowth of fungi. Changes in
diet provide novel substrates supporting bacterial growth.Cell HostInflammation may select for bacterial taxa able to live in the
setting of oxidative stress. The normal oxygen gradient in the co-
lon influences the composition of the gutmicrobiota with a higher
abundance of Proteobacteria in themicroaerobic environment of
the mucosal surface (Albenberg et al., 2014). Disruption of the
epithelium and bleeding due to active Crohn’s disease is ex-
pected to lead to greater intraluminal oxygen, which in turn
would favor outgrowth of taxa belonging to the Proteobacteria
phylum. In addition, some Enterobacteriacaea are known to
exploit compounds produced during inflammation as terminal
electron acceptors, promoting their outgrowth (Winter and
Ba¨umler, 2014).
We observed a rapid change in the composition of the gut mi-
crobiota within 1 week of initiating EEN, similar to that observed
in other small studies of defined formula diets (Gerasimidis et al.,
2014) and with alterations in whole-food diets (David et al., 2014;
Wu et al., 2011). However, this study was unique in the ability to
compare PEN to EEN. A similar change in themicrobiota was not
observed in children receiving PEN, despite administration of
nearly the same amount of enteral formula, suggesting that the
exclusion of table foods was the primary determinant in chang-
ing the gut microbiota and perhaps mediating the increased
effectiveness of EEN (Lee et al., 2015). After 1 week of EEN,
the composition of the microbiota differed between ultimate re-
sponders and non-responders, suggesting measures of the mi-
crobiota may be used to predict response to therapy.
Genes from the category ‘‘biosynthesis of siderophore group
nonribosomal peptides’’ (Figure 2A) were more represented in
the more dysbiotic far cluster. This may be due to the response
of the gut microbiota to blood in the gut lumen, as indicated by
the association with human DNA in stool. Siderophores scav-
enge iron from the environment. Iron has been linked to an inva-
sive phenotype in bacteria, thereby promoting inflammation
(Nairz et al., 2010). Thus, blood associated with active IBD may
deliver iron to the gut microbiota, promoting dysbiosis.
The effect of environmental stress on the gut microbiota ex-
tends into the Eukaryotic domain. Others have documented& Microbe 18, 489–500, October 14, 2015 ª2015 Elsevier Inc. 497
increased richness of fungi in patients with Crohn’s disease us-
ing older methods but have not linked this directly to specific
fungi, environmental stressors, or linked changes in the bacterial
microbiota (Ott et al., 2008; Richard et al., 2015). In a separate
study using sequencing of fungal gene tags, we found that
Cyberlindnera jadinii (also known as Pichia jadinii or Candida
utilis) was proportionally increased in Crohn’s patients (Chehoud
et al., 2015), confirming the detection of this lineage here. In this
study, four of the five fungi detected (Candida, Clavispora, Cy-
berlindnera, and Kluyveromyces) showed increased representa-
tion in Crohn’s disease samples at baseline in the absence of
antiboitic use. Independently, antibiotic use was also associated
with increased colonization by all five fungi. Diet therapy showed
the opposite behavior—after 1 week, fungal colonization was
diminished (Figure 5). Thus increased fungal colonization is
associated independently with disease and antibiotic treatment
and diminished with EEN. The reduction with EEN may be a
consequence of lower consumption of fungi in food (Saccharo-
myces and Cyberlindnera are both found in foods), or due to a
change in the microbial environment in the gut with EEN, paral-
leling the change in bacteria. The importance for pathogenesis
is unknown, though we note that anti-Saccharomyces antibio-
dies are used as a biomarker in IBD (Peeters et al., 2001; Pri-
deaux et al., 2012; Quinton et al., 1998), and fungi have shown
to exacerbate colitis in mouse models (Iliev et al., 2012).
Cyberlindnera and Candida have been positively associated
with bacteria including Streptococcus and Lactobacillus. Posi-
tive correlation ofCandida andStreptococcus has been reported
for oral samples from lung transplant recipients (Bittinger et al.,
2014), an interaction proposed in medically important mixed bio-
films (Metwalli et al., 2013). Possibly antibiotic exposure pro-
motes formation of a mixed community in the inflamed gut,
paralleling studies in mice (Dollive et al., 2013).
The presence of fungi may also have contributed to the meta-
bolic genomic signature associated with IBD (Figures 2A and
2C). Since bacteria do not have phospholipid membranes as in
eukaryotic organisms, it may be that the predominance of genes
associated with ‘‘glycerolipid metabolism’’ and ‘‘glycerol phos-
pholipid metabolism’’ (Figure 2C) in Crohn’s disease is due to
the abundance of fungi in the dysbiotic far cluster. Indeed, with
the exception of actinomycetes group, triacylglycerols in bacte-
ria have rarely been described (Alvarez and Steinbu¨chel, 2002).
These same pathways might also be involved in the catabolism
of fatty acid lipids through either peroxisomal or mitochondrial
b-oxidation, again, a feature of eukaryotic organisms like yeast
(Strijbis and Distel, 2010) and not bacteria.
The bacterial microbiota among responders became more
similar to the healthy controls than the microbiota of non-re-
sponders with both anti-TNF and EEN. Anti-TNF therapy is
administered parenterally and is not expected to alter the gut
microbiome directly, indicating that dysbiosis is likely a conse-
quence of inflammation. However, the bacterial dysbiosis was
only partially resolved among responders, and fungal dysbiosis
did not resolve. Perhaps complete resolution would occur with
longer follow-up along with a reduction in the stressors to the
gut microbiota described here. In turn, complete resolution of
bacterial and or fungal dysbiosis might have a favorable
impact on Crohn’s disease (Rajca et al., 2014; Samuel et al.,
2010).498 Cell Host & Microbe 18, 489–500, October 14, 2015 ª2015 ElsevIn conclusion, we document that dysbiosis of Crohn’s disease
extends beyond bacteria to include fungi. The dysbiosis results
from a combination of inflammation, antibiotic exposure, and
dietary changes, each exerting different impacts on the gut mi-
crobiota composition. EEN caused further departure of the
composition of the gut bacteria from the pattern of healthy con-
trols within 1 week, likely due to the elimination of table foods,
but was effective in reducing inflammation. The extent of dysbio-
sis diminished with reduction of inflammation by anti-TNF or
EEN, consistent with inflammation contributing directly to the
dysbiosis. Gene pathway analysis suggested that the gut micro-
biota responds to gut environmental stressors through themodi-
fication of metabolism. Thus, while dysbiosis in general is
common to Crohn’s disease, the nature of the dysbiosis is
unique to each environmental stressor. Future studies should
explore whether these effects interact in ways that influence
outcome.EXPERIMENTAL PROCEDURES
Metagenomic Analysis
Details on human subjects are reported in Lee et al. (2015) and in the Supple-
mental Experimental Procedures. We enrolled children under age 22 with
active disease defined as a Pediatric Crohn’s Disease Activity Index (PCDAI)
score greater than 10 who were initiating therapy with either EEN, PEN, or
anti-TNF agent. Therapy was chosen by the attending physician. We excluded
children with an ostomy, treatment with probiotics in the prior 2 weeks,
receiving more than 50% of daily calories from parenteral nutrition, who
used anti-TNF therapy within 8 weeks prior to starting EEN or PEN, or who
used a EEN or PEN within 1 week of starting anti-TNF therapy. Patients had
stool samples collected for determining FCP concentration and microbiome
characterization at baseline, 1 week, 4 weeks, and 8 weeks following initiation
of the treatment. Reduction in inflammation was assessed with FCP concen-
tration, which is correlated with endoscopic findings of mucosal inflammation
and decreases following initiation of medications in active Crohn’s disease(Le-
wis, 2011; Summerton et al., 2002). For this study, we defined response
to therapy as a reduction in FCP to %250 mg/g among those with baseline
FCP > 250 mg/g.
Stool samples (n = 366) were stored for up to 48 hr on ice, then frozen
at 80C. DNA was purified from each sample using the MoBio PowerSoil
kit. Libraries for DNA sequencing were prepared using the TruSeq method,
and sequence was acquired using the Illumina HiSeq method (Illumina).
Reads were preprocessed based on quality scores using the FASTX suite
with default parameters. This yielded 8.7 3 1011 total bases of sequence.
The amount of sequence collected for each sample is summarized in Table
S1A. Using BMtagger, we next identified and removed human reads from
the quality filtered reads. The bacterial abundance was quantified by Meta-
PhlAn. We filtered out the samples with non-human reads <30,000 and bacte-
rial genera with max abundance <1% across all samples or present in <0% of
all samples. The distance between samples was measured by the Jaccard in-
dex. The pamk function in R package fpc was used to find the optimal clus-
tering of bacterial data. Gene pathway abundance was measured by
HUMAnN.We filtered out low abundance gene pathwayswithmax abundance
<0.1% across all samples or present in <0 samples. We used the Bray-Curtis
distance to measure the distance between samples for the pathway data. The
R package quantreg was used for quantile regression with quantile set to 75%.
We used the log fold change of abundance at week 8 over baseline as the
response variable and treatments, antibiotic use, response status as the cova-
riates in the quantile regression. To avoid dividing by the zero value or taking
log of the zero value, we added the smallest non-zero abundance value to
the abundance before calculating the log fold change. All p values in the above
analysis were adjusted by the FDR (Benjamini-Hochberg) method for multiple
comparisons except where noted.
Human DNA was quantified using ABI Taqman Gene Expression Assay
Hs00742533_s1. Instant JChem was used for structure databaseier Inc.
management, search, and prediction, Instant JChem 5.9.4, (2012-02-10),
ChemAxon (http://www.chemaxon.com). Viral sequences were detected by
BLAST alignment to the NCBI viral database. Archaeal sequences were de-
tected by alignment to the M. smithii genome. Fungal sequences were de-
tected and quality filtered as described in the Supplemental Information:
Filtering procedure for analysis of fungal alignments.
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